Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls

Journal of Proteomics

Volumn 76, Issue , 2012, Pages 43-55

  Jaros, Julian A J ^a   Martins de Souza, Daniel ^b   Rahmoune, Hassan ^a   Rothermundt, Matthias ^c,d   Leweke, F Markus ^e,f   Guest, Paul C ^a   Bahn, Sabine ^a,g  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c Evangelisches und Johanniter Klinikum Niederrhein   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biomarker; Blood transporter; Complement system; Functional change; IMAC; LC MSE

Indexed keywords

ALSIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANGIOTENSINOGEN; ANTITHROMBIN III; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; CARBONATE DEHYDRATASE I; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT FACTOR H RELATED PROTEIN 3; FIBRINOGEN A ALPHA CHAIN; FICOLIN 3; INTER ALPHA TRYPSIN INHIBITOR HCH3; KERATIN; KINESIN LIKE PROTEIN KIF21B; LEUCINE RICH REPEAT CONTAINING PROTEIN 7; LEUKEMIA INHIBITOR FACTOR RECEPTOR; MICROTUBULE ASSOCIATED SERINE THREONIN PORTEIN KINASE 1; MYOFERLIN; NUCLEOBINDIN 1; PHOSPHATIDYLINOSITOL GLYCAN SPECIFIC PHOSPHOLIPASE D; PLASMINOGEN; PROTEIN; PROTHROMBIN; RETINOL BINDING PROTEIN 4; SARCOMA ANTIGEN 1; SOMATOMEDIN BINDING PROTEIN 3; SORBIN; TETRANECTIN; UNCLASSIFIED DRUG; WD REPEAT CONTAINING PROTEIN 19; XIN ACTIN BINDING REPEAT CONTAINING PROTEIN 1;

AMINO ACID SEQUENCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; SCHIZOPHRENIA; UNINDEXED SEQUENCE;

ADULT; BIOLOGICAL MARKERS; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEOMICS; SCHIZOPHRENIA;

EID: 84869882560     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.05.027     Document Type: Article

References (92)

1. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality. Epidemiol Rev 2008, 30:67-76.
2. Thaker G.K., Carpenter W.T. Advances in schizophrenia. Nat Med 2001, 7:667-671.
3. Tsuang M.T., Lyons M.J., Faraone S.V. Heterogeneity of schizophrenia. Conceptual models and analytic strategies. The British Journal of Psychiatry. J Ment Sci 1990, 156:17-26.
4. Tateyama M., Kudo I., Hashimoto M., Abe Y., Kainuma A., Yoshimura K., et al. Is paranoid schizophrenia the most common subtype? Comparison of subtype diagnoses by Japanese and European psychiatrists, using the summaries of the same patients. Psychopathology 1999, 32:98-106.
5. Javitt D.C., Spencer K.M., Thaker G.K., Winterer G., Hajos M. Neurophysiological biomarkers for drug development in schizophrenia. Nat Rev Drug Discov 2008, 7:68-83.
6. English J.A., Dicker P., Föcking M., Dunn M.J., Cotter D.R. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 2009, 9:3368-3382.
7. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T.-J., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004, 9:684-697. [643].
8. Huang J.T.-J., Wang L., Prabakaran S., Wengenroth M., Lockstone H.E., Koethe D., et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 2008, 13:1118-1128.
9. Huang J.T.-J., Leweke F.M., Tsang T.M., Koethe D., Kranaster L., Gerth C.W., et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2007, 2:e756.
10. Martins-De-Souza D., Wobrock T., Zerr I., Schmitt A., Gawinecka J., Schneider-Axmann T., et al. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry 2010, 11:719-728.
11. Herberth M., Koethe D., Cheng T.M.K., Krzyszton N.D., Schoeffmann S., Guest P.C., et al. Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. Mol Psychiatry 2010, 16:848-859.
12. Levin Y., Wang L., Schwarz E., Koethe D., Leweke F.M., Bahn S. Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol Psychiatry 2009, 15:1088-1100.
13. Schwarz E., Bahn S. Biomarker discovery in psychiatric disorders. Electrophoresis 2008, 29:2884-2890.
14. Cheng T.M.K., Lu Y.-E., Guest P.C., Rahmoune H., Harris L.W., Wang L., et al. Identification of targeted analyte clusters for studies of schizophrenia. Mol Cell Proteomics 2010, 9:510-522.
15. Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J.P., Guest P.C., et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights 2010, 5:39-47.
16. Martins-de-Souza D., Guest P.C., Vanattou-Saifoudine N., Wesseling H., Rahmoune H., Bahn S. The need for phosphoproteomic approaches in psychiatric research. J Psychiatr Res 2011, 45:1404-1406.
17. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
18. Schmidt S.R., Schweikart F., Andersson M.E. Current methods for phosphoprotein isolation and enrichment. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 849:154-162.
19. Zolnierowicz S., Bollen M. Protein phosphorylation and protein phosphatases. De Panne, Belgium, September 19-24, 1999. EMBO J 2000, 19:483-488.
20. Walaas S.I., Greengard P. Protein phosphorylation and neuronal function. Pharmacol Rev 1991, 43:299-349.
21. Panariello F., Perruolo G., Cassese A., Giacco F., Botta G., Barbagallo A.P.M., et al. Clozapine impairs insulin action by up-regulating Akt phosphorylation and Ped/Pea-15 protein abundance. J Cell Physiol 2011, 227:1485-1492.
22. Jaros J.A.J., Martins-de-Souza D., Rahmoune H., Schwarz E., Leweke F.M., Guest P.C., et al. Differential phosphorylation of serum proteins reflecting inflammatory changes in schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2011, 10.1007/s00406-011-0283-6.
23. Hoffman S.A., Joo W.A., Echan L.A., Speicher D.W. Higher dimensional (Hi-D) separation strategies dramatically improve the potential for cancer biomarker detection in serum and plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 849:43-52.
24. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
25. Koutroukides T.A., Guest P.C., Leweke F.M., Bailey D.M.D., Rahmoune H., Bahn S., et al. Characterization of the human serum depletome by label-free shotgun proteomics. J Sep Sci 2011, 34:1621-1626.
26. Roche S., Tiers L., Provansal M., Seveno M., Piva M.-T., Jouin P., et al. Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: the more the better?. J Proteomics 2009, 72:945-951.
27. Faca V., Pitteri S.J., Newcomb L., Glukhova V., Phanstiel D., Krasnoselsky A., et al. Contribution of protein fractionation to depth of analysis of the serum and plasma proteomes. J Proteome Res 2007, 6:3558-3565.
28. Smith M.P.W., Wood S.L., Zougman A., Ho J.T.C., Peng J., Jackson D., et al. A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics 2011, 11:2222-2235.
29. Tang H.-Y., Beer L.A., Barnhart K.T., Speicher D.W. Rapid Verification of Candidate Serological Biomarkers Using Gel-based, Label-free Multiple Reaction Monitoring. J Proteome Res 2011, 10:4005-4017.
30. Zhao L, Liu Y, Sun X, Peng K, Ding Y. Serum proteome analysis for profiling protein markers associated with lymph node metastasis in colorectal carcinoma. J Comp Pathol n.d.;144:187-94.
31. Liao Q., Zhao L., Chen X., Deng Y., Ding Y. Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma. Clin Exp Metastasis 2008, 25:465-476.
32. Hamrita B., Chahed K., Trimeche M., Guillier C.L., Hammann P., Chaïeb A., et al. Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin Chim Acta 2009, 404:111-118.
33. Kaur P., Reis M.D., Couchman G.R., Forjuoh S.N., Greene J.F., Asea A. SERPINE 1 Links Obesity and Diabetes: A Pilot Study. J Proteomics Bioinform 2010, 3:191-199.
34. Levin Y., Jaros J.A., Schwarz E., Bahn S. Multidimensional protein fractionation of blood proteins coupled to data-independent nanoLC-MS/MS analysis. J Proteomics 2010, 73:689-695.
35. Dubrovska A., Souchelnytskyi S. Efficient enrichment of intact phosphorylated proteins by modified immobilized metal-affinity chromatography. Proteomics 2005, 5:4678-4683.
36. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Fam Pract 2004, 21:4-10.
37. World Health Organization International Statistical Classification of Diseases and Related Health Related Problems (ICD) 2010, World Health Organization, Geneva. 4th edition.
38. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
39. Krishnamurthy D., Harris L.W., Levin Y., Koutroukides T.A., Rahmoune H., Pietsch S., et al. Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects. World J Biol Psychiatry 2012.
40. Martins-de-Souza D., Guest P.C., Mann D.M., Roeber S., Rahmoune H., Bauder C., et al. Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration. J Proteome Res 2012, 11:2533-2543.
41. Herberth M., Koethe D., Levin Y., Schwarz E., Krzyszton N.D., Schoeffmann S., et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics 2011, 11:94-105.
42. Yu Y.Q., Campuzano I., Gilar M. Enhanced nanoLC/MS analysis of phosphopeptides. Application Note 2006, Waters Corporation, Milford, USA.
43. Bateman R.H., Carruthers R., Hoyes J.B., Jones C., Langridge J.I., Millar A., et al. A novel precursor ion discovery method on a hybrid quadrupole orthogonal acceleration time-of-flight (Q-TOF) mass spectrometer for studying protein phosphorylation. J Am Soc Mass Spectrom 2002, 13:792-803.
44. Li G.-Z., Golick D., Gorenstein M.V., Vissers J.P.C., Silva J.C., Geromanos S.J.W.C. A novel ion accounting algorithm for protein database searches. Proceedings of the Human Proteome Organisation (HUPO) 5th Annual World Congress 2006.
45. Li G.-Z., Vissers J.P.C., Silva J.C., Golick D., Gorenstein M.V., Geromanos S.J. Database searching and accounting of multiplexed precursor and product ion spectra from the data independent analysis of simple and complex peptide mixtures. Proteomics 2009, 9:1696-1719.
46. Yang X., Levin Y., Rahmoune H., Ma D., Schöffmann S., Umrania Y., et al. Comprehensive two-dimensional liquid chromatography mass spectrometric profiling of the rat hippocampal proteome. Proteomics 2011, 11:501-505.
47. Stelzhammer V., Rothermundt M., Guest P.C., Michael N., Sondermann C., Kluge W., et al. Proteomic changes induced by anaesthesia and muscle relaxant treatment prior to electroconvulsive therapy. Proteomics Clin Appl 2011, 5:644-649.
48. Martins-de-Souza D., Guest P.C., Steeb H., Pietsch S., Rahmoune H., Harris L.W., et al. Characterizing the proteome of the human dorsolateral prefrontal cortex by shotgun mass spectrometry. Proteomics 2011, 11:2347-2353.
49. Lu P., Vogel C., Wang R., Yao X., Marcotte E.M. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol 2007, 25:117-124.
50. Hart S.R., Lau K.W., Hao Z., Broadhead R., Portman N., Hühmer A., et al. Analysis of the trypanosome flagellar proteome using a combined electron transfer/collisionally activated dissociation strategy. J Am Soc Mass Spectrom 2009, 20:167-175.
51. Rosenthal A.K., Gohr C.M., Ninomiya J., Wakim B.T. Proteomic analysis of articular cartilage vesicles from normal and osteoarthritic cartilage. Arthritis Rheum 2011, 63:401-411.
52. Vissers J.P.C., Langridge J.I., Aerts J.M.F.G. Analysis and quantification of diagnostic serum markers and protein signatures for Gaucher disease. Mol Cell Proteomics 2007, 6:755-766.
53. Choi H., Nesvizhskii A.I. False discovery rates and related statistical concepts in mass spectrometry-based proteomics. J Proteome Res 2008, 7:47-50.
54. Rothman K.J. No Adjustments Are Needed for Multiple Comparisons. Epidemiology January 1990, 1(1):43-46.
55. Calvano S.E., Xiao W., Richards D.R., Felciano R.M., Baker H.V., Cho R.J., et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037.
56. Ramazan Sekeroǧlu M., Aydin S., Dülger H., Yilmaz Y., Bayrakli H., Noyan T. Diagnostic value of cytokeratin-18 as a tumor marker in bladder cancer. Clin Biochem 2002, 35:327-331.
57. Melissourgos N.D., Kastrinakis N.G., Skolarikos A., Pappa M., Vassilakis G., Gorgoulis V.G., et al. Cytokeratin-20 immunocytology in voided urine exhibits greater sensitivity and reliability than standard cytology in the diagnosis of transitional cell carcinoma of the bladder. Urology 2005, 66:536-541.
58. Ostergaard M., Rasmussen H.H., Nielsen H.V., Vorum H., Orntoft T.F., Wolf H., et al. Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res 1997, 57:4111-4117.
59. Schenk S., Schoenhals G.J., de Souza G., Mann M. A high confidence, manually validated human blood plasma protein reference set. BMC Med Genomics 2008, 1:41.
60. Ali I.U. Phosphorylation of fibronectin in quiescent and growing cell cultures. FEBS Lett 1983, 151:45-48.
61. Yamada K.M. Cell surface interactions with extracellular materials. Annu Rev Biochem 1983, 52:761-799.
62. Féron F., Perry C., Hirning M.H., McGrath J., Mackay-Sim A. Altered adhesion, proliferation and death in neural cultures from adults with schizophrenia. Schizophr Res 1999, 40:211-218.
63. Wang L., Lockstone H.E., Guest P.C., Levin Y., Palotás A., Pietsch S., et al. Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia. J Proteome Res 2010, 9:521-527.
64. De Corte V., Demol H., Goethals M., Van Damme J., Gettemans J., Vandekerckhove J. Identification of Tyr438 as the major in vitro c-Src phosphorylation site in human gelsolin: a mass spectrometric approach. Protein Sci 1999, 8:234-241.
65. Peddada N., Sagar A., Ashish, Garg R. Plasma gelsolin: A general prognostic marker of health. Med Hypotheses 2011, 78:203-210.
66. Haddad J.G., Harper K.D., Guoth M., Pietra G.G., Sanger J.W. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci U S A 1990, 87:1381-1385.
67. Takiguchi K., Yamashiro-Matsumura S., Matsumura F. Artificial phosphorylation removes Gelsolin's dependence on calcium. Cell Struct Funct 2000, 25:57-65.
68. Baugh R.F., Hougie C. The chemistry of blood coagulation. Clin Haematol 1979, 8:3-30.
69. Masopust J., Malý R., Andrýs C., Vališ M., Bažant J., Hosák L. Markers of thrombogenesis are activated in unmedicated patients with acute psychosis: a matched case control study. BMC Psychiatry 2011, 11:2.
70. Zhou W., Janulis L., Park I.I., Lee C. A novel anti-proliferative property of clusterin in prostate cancer cells. Life Sci 2002, 72:11-21.
71. Lemansky P., Brix K., Herzog V. Subcellular distribution, secretion, and posttranslational modifications of clusterin in thyrocytes. Exp Cell Res 1999, 251:147-155.
72. Xie Z., Harris-White M.E., Wals P.A., Frautschy S.A., Finch C.E., Morgan T.E. Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. J Neurochem 2005, 93:1038-1046.
73. Schrijvers E.M.C., Koudstaal P.J., Hofman A., Breteler M.M.B. Plasma clusterin and the risk of Alzheimer disease. JAMA 2011, 305:1322-1326.
74. Furlong C.E., Suzuki S.M., Stevens R.C., Marsillach J., Richter R.J., Jarvik G.P., et al. Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact 2010, 187:355-361.
75. Morera A.L., Henry M., García-Hernández A., Fernández-López L. Acute phase proteins as biological markers of negative psychopathology in paranoid schizophrenia. Actas Esp Psiquiatr 2007, 35:249-252.
76. Strous R.D., Shoenfeld Y. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 2006, 27:71-80.
77. Boyajyan A.S., Khoyetsyan A.G., Hakobyan S.S., Tsakanova G.V., Ayvazyan V.A. Hyperactivation of the alternative complement cascade in schizophrenia. Dokl Biochem Biophys 2008, 419:56-57.
78. Mayilyan K.R., Weinberger D.R., Sim R.B. The complement system in schizophrenia. Drug News Perspect 2008, 21:200-210.
79. Muller N., Schwarz M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 2006, 10:131-148.
80. Nilsson-Ekdahl K., Nilsson B. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1. Eur J Immunol 2001, 31:1047-1054.
81. Hermoso T., Fishelson Z., Becker S.I., Hirschberg K., Jaffe C.L. Leishmanial protein kinases phosphorylate components of the complement system. EMBO J 1991, 10:4061-4067.
82. Bohana-Kashtan O., Pinna L.A., Fishelson Z. Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis. Eur J Immunol 2005, 35:1939-1948.
83. du Bois T.M., Deng C., Huang X.-F. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:878-888.
84. Yao J.K., van Kammen D.P. Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiol 2004, 59:297-326.
85. Voegele A.F., Jerković L., Wellenzohn B., Eller P., Kronenberg F., Liedl K.R., et al. Characterization of the vitamin E-binding properties of human plasma afamin. Biochemistry 2002, 41:14532-14538.
86. Jerkovic L., Voegele A.F., Chwatal S., Kronenberg F., Radcliffe C.M., Wormald M.R., et al. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J Proteome Res 2005, 4:889-899.
87. Kratzer I., Bernhart E., Wintersperger A., Hammer A., Waltl S., Malle E., et al. Afamin is synthesized by cerebrovascular endothelial cells and mediates alpha-tocopherol transport across an in vitro model of the blood-brain barrier. J Neurochem 2009, 108:707-718.
88. Vatassery G.T., Quach H.T., Smith W.E., Santacruz K.S., Roy S. Apolipoprotein e deficiency leads to altered brain uptake of alpha tocopherol injected into lateral cerebral ventricles. Biochim Biophys Acta 2007, 1772:797-803.
89. Qin Z., Qin Y., Liu S. Alteration of DBP levels in CSF of patients with MS by proteomics analysis. Cell Mol Neurobiol 2009, 29:203-210.
90. Disanto G., Ramagopalan S.V., Para A.E., Handunnetthi L. The emerging role of vitamin D binding protein in multiple sclerosis. J Neurol 2011, 258:353-358.
91. Takahashi N., Sakurai T., Davis K.L., Buxbaum J.D. Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol 2011, 93:13-24.
92. Guest P.C., Wang L., Harris L.W., Burling K., Levin Y., Ernst A., et al. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients. Mol Psychiatry 2010, 15:118-119.